Evidence map›Paper›PMID 42599961›Full record

ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2026

PCK2 Inhibition Reverses Cisplatin Resistance of Non-Small Cell Lung Cancer by Triggering Ferroptosis.

Jing Liu, Ziyan Wang, Chen Gu, Yili Chen, Yang Yang, Jianjie Zhu, Yihua Zhang, Yuna Shao, Xiaodong Pang, Yujie Ge and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Jing LiuDepartment of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Soochow University, Suzhou, China.
Ziyan WangDepartment of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Soochow University, Suzhou, China.
Chen GuDepartment of Respiratory Medicine, Taixing Second People's Hospital, Taixing, China.
Yili ChenDepartment of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Soochow University, Suzhou, China.
Yang YangDepartment of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Soochow University, Suzhou, China.
Jianjie ZhuDepartment of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Soochow University, Suzhou, China.
Yihua ZhangDepartment of Pharmacy, The First Affiliated Hospital of Soochow University, Suzhou, China.
Yuna ShaoDepartment of Pharmacy, The First Affiliated Hospital of Soochow University, Suzhou, China.
Xiaodong PangDepartment of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Soochow University, Suzhou, China.
Yujie GeDepartment of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Soochow University, Suzhou, China.
Huiwen QianDepartment of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Soochow University, Suzhou, China.
Jian-An HuangDepartment of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Soochow University, Suzhou, China.
Zeyi LiuDepartment of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Soochow University, Suzhou, China.
Yuanyuan ZengDepartment of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Soochow University, Suzhou, China.ORCID https://orcid.org/0000-0002-3589-7415
Cheng JiDepartment of Pulmonary and Critical Care Medicine, Lung Cancer Center, The First Affiliated Hospital of Soochow University, Suzhou, China.

Funding

Clinical diagnosis and Treatment Technology Innovation Project CXZL-F-240701Jiangsu Provincial Medical Key Discipline ZDXK202201National Nature Science Foundation of China 82272648
6 · The paper itself

Abstract

Non-small cell lung cancer (NSCLC) accounts for ~85% of lung cancers, with platinum-based chemotherapy as the main treatment. Ferroptosis has been implicated in cancer chemoresistance, yet the molecular mechanisms linking metabolic reprogramming to ferroptosis-mediated cisplatin resistance in NSCLC remain elusive. In this study, we found that phosphoenolpyruvate carboxykinase 2 (PCK2), a metabolic reprogramming enzyme, was significantly upregulated, and its overexpression enhanced ferroptosis resistance, thereby promoting cisplatin chemoresistance. Mechanistically, RGB-286638 free base (RGB) inhibits PCK2 expression by directly binding to its R454 site to activate ferroptosis in cisplatin-resistant cells and restores cisplatin sensitivity both in vitro and in vivo. Targeting PCK2 with RGB provides a promising strategy to overcome chemoresistance, facilitating improved clinical interventions for NSCLC.

Indexed as

Carcinoma, Non-Small-Cell LungCisplatinDrug Resistance, NeoplasmFerroptosisLung NeoplasmsPhosphoenolpyruvate Carboxykinase (GTP)AnimalsAntineoplastic AgentsCell Line, TumorGene Expression Regulation, NeoplasticHumansMiceMice, NudeAntineoplastic AgentsCisplatinPhosphoenolpyruvate Carboxykinase (GTP)CisplatinFerroptosisNSCLCPCK2RGB‐286638 free base

Identifiers

PMID42599961
PMCPMC13475953

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.